Synonyms: compound 1 [PMID: 31012583] | FX301 | PCRX301 | TV-45070 | TV45070 | XEN-402 | XEN402 | XPF-002
Compound class:
Synthetic organic
Comment: Funapide (XEN-402) is a NaV1.7 channel inhibitor that is proposed for analgesic activity [1].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Funapide (TV-45070) has undergone clinical evaluations for potential to treat chronic pain conditions. More recently the focus has switched to post-operative acute pain. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT00001693 | Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers | Phase 1 Interventional | National Institutes of Health Clinical Center (CC) | ||
NCT02068599 | A Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (Ointment) in Participants With Primary Osteoarthritis (OA) Affecting a Single Knee | Phase 2 Interventional | Teva Branded Pharmaceutical Products R&D, Inc. | ||
NCT01195636 | A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN) | Phase 2 Interventional | Xenon Pharmaceuticals Inc. | ||
NCT04826328 | Study to Evaluate the Safety and Tolerability of FX301 in Patients Undergoing Bunionectomy | Phase 1 Interventional | Flexion Therapeutics, Inc. |